Sophisticated protein engineering has largely been the domain of major biopharmaceutical companies. But genomics is flooding researchers with new proteins of unknown function and traditional techniques for turning them into drugs or for understanding their potential as drug targets are generally too slow. Start-ups around phage display, protein evolution, and synthetic protein chemistries are offering what look like faster, cheaper alternatives. But the size of the partnership opportunity for these new companies is uncertain, since drug companies still appear reluctant to embark on the development of protein drugs. In response, the start-ups are also trying to exploit the technologies for small-molecule drug discovery.
by Roger Longman
Nature never engineered proteins for use as pharmaceuticals, says Richard DiMarchi, PhD, VP of research technologies and proteins at Eli...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.
The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.
EFPIA says reforms make the continent less attractive for innovative firms.
US green light will further expand sales of the prostate cancer blockbuster.
As the patent protection clock ticks down on Merck’s flagship blockbuster Keytruda, the company is reported to be pursuing the inflammation and immunology biotech. Such a move would bulk up its sparse I&I pipeline.
EFPIA says reforms make the continent less attractive for innovative firms.
Plus deals involving Roche/Vividion, Alto/Chase, Biogen/City Therapeutics, Sanofi/Nurix and Naya/Invo.
